6-KThe Wire
Enlivex Ltd. files 6-K
Filed May 18, 2026 · 1mo ago · Accession 0001213900-26-058130
Plain English
Enlivex Ltd. announced the dosing of the first patient in a United States clinical site for its Phase 2b clinical trial of Allocetra™ for moderate-to-severe age-related symptomatic primary knee osteoarthritis. This marks a step forward in the development of their therapeutic candidate.
Filing details
- Company
- Enlivex Ltd.
- Ticker
- ENLV
- CIK
- 1596812
- Form type
- 6-K
- Filing date
- May 18, 2026
- Report date
- May 18, 2026
- Document
- ea0291229-6k_enlivex.htm
- Size
- 33 KB